Nixon & Vanderhye P.C.
Method for treating a disease originated from receptor activation by EREG and TGFα
The present inventors identified inhibition of a combination of EGFR ligands that serve as targets for inhibition of cancer cell proliferation. More specifically, EREG antagonists and TGFα antagonists were found to be useful as inhibitors of cell growth. The present invention relates to pharmaceutical compositions containing EGF family ligand antagonists as components.
CHUGAI SEIYAKU KABUSHIKI KAISHA
C C G A G A G A A C A A A A C A A C C
C07K C07K G01N A61P G01N A61P G01N A61P A61P C07K A61K A61P A61K A61P C07K A61P A61K C07K C07K
additional additional additional inventional additional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional additional additional additional
Hirotaka Kenji
Ito Yoshida